Aktiesnakken — Juli 2012
-
genmab blev afvist kraftigt ved 60
-
tror der skal en daradeal til før vi kan bryde desværre.
-
syntes nu ikke der er så stort et salgspres. der er bare ikke ingen købere der vil give 60+
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind